WAVE Life Sciences Ltd. is a biotechnology company that specializes in the development of nucleic acid therapeutics. The company's proprietary platform allows for the design and optimization of synthetic nucleic acid molecules that can selectively target and modulate the expression of disease-causing genes. WAVE's pipeline includes programs in Huntington's disease, Duchenne muscular dystrophy, and various other genetic disorders. The company was founded in 2012 and is headquartered in Singapore, with additional offices in Cambridge, Massachusetts and Tokyo, Japan.